tbuckley/cabot-search huggingface dataset:
CMET-36. IMMUNOTHERAPY VERSUS STANDARD OF CARE IN MELANOMA BRAIN METASTASES WITH KNOWN BRAF STATUS
Authors: Addison Barnett, Soumya Sagar, Adam Lauko, Wei (Auston) Wei, Samuel Chao, David Peereboom, Glen Stevens, Lilyana Angelov, Jennifer Yu, Erin Murphy, Alireza Mohammadi, John Suh, Gene Barnett, Manmeet Ahluwalia
Journal: Neuro-Oncology (2019)

Abstract INTRO/OBJECTIVE A mutation of the BRAF protein is seen in approximately 50% of melanoma patients. Immune checkpoint inhibitors (ICI) are standard therapy in melanoma patients independent of a patient’s BRAF status. The primary objective of this study is to investigate the impact of BRAF status in patients treated with ICI compared to non-ICI systemic therapy on overall survival (OS) in patients with melanoma brain metastasis (MBM). METHODS We reviewed 351 patients with MBM treated at our tertiary care center between 2000 and 2018. Of these, 144 had known BRAF status, 71 of which were BRAF mutant and 73 were BRAF wild-type. OS was calculated from the date of diagnosis of MBM to compare the efficacy of ICI to other systemic therapies. Many of these patients received multiple lines of treatment including targeted therapies at some point during their care. The log-rank test and Cox proportional hazard model was utilized to determine differences in OS. RESULTS Eighty-four percent of patients received local therapy that included either surgery, stereotactic radiosurgery, or whole brain radiation therapy. In BRAF wild-type patients, 40 received ICI and 33 underwent non-ICI systemic therapy with a median survival (5.6 vs 7.1 months) and 2-year survival (28% vs 32%), respectively (p=0.64). Of the BRAF mutant patients, 33 received ICI and 38 did not with a median survival (17.1 vs 9.0 months) and 2-year survival (36% and 19%), respectively (p=0.014). When controlling for age, KPS, ECM, and number of lesions, BRAF mutant MBM patients treated with ICI compared to non-ICI had an OS hazard ratio, HR=0.4 (95% CI=0.21 – 0.78, p=0.0069). CONCLUSION ICI therapy in BRAF mutant MBM patients results in improved OS compared to those with non-ICI systemic therapy. No such difference was observed in the BRAF wild-type cohort.
Targeting of CD19 By Tafasitamab Does Not Impair CD19 Directed Chimeric Antigen Receptor T Cell Activity in Vitro
Authors: Paulina Horvei, Reona Sakemura, Michelle J. Cox, Michael W. Ruff, Mehrdad Hefazi, Erin E. Tapper, Kendall J. Schick, Claudia Manriquez Roman, Charles J. Kuhlmann, Juergen Schanzer, Jan Endell, Grzegorz Nowakowski, Neil E. Kay, Saad S. Kenderian
Journal: Blood (2019)
P1.17 How to Visualize Exosomes in NSCLC: “The New Guest Star in the Liquid Biopsy Movie”
Authors: S. Taverna, P. Reclusa, P. Verstraelen, D. De Miguel-Pérez, M. Pucci, I. Pintelon, N. Claes, M. Gunasekaran, R. Alessandro, S. Bals, S. Kaushal, C.D. Rolfo
Journal: Journal of Thoracic Oncology (2019)
EXTH-54. MULTIVALENT TARGETED PROTEINS FOR GLIOBLASTOMA TREATMENT
Authors: Puja Sharma, Denise Herpai, John Rossmeisl, Stephen Tatter, Waldemar Debinski
Journal: Neuro-Oncology (2019)

Abstract A heterogeneous and infiltrating tumor like glioblastoma (GBM) cannot be effectively treated with a single-targeted therapy. Hence, targeting several GBM-associated factors that are responsible for the disease progression and/or recurrence at once is a way to address the issue of tumor heterogeneity. Building on a Phase I clinical trial of a cytotoxic cocktail targeting IL-13-RA2 and EphA2 receptors showing dramatic anti-tumor responses in dogs with spontaneous gliomas, we have developed multivalent single pharmaceutical agents that target four specific to GBM receptors: IL-13RA2, EphA2, EphA3, and EphB2. The combined expression of these receptors spans almost 100% of the tumor microenvironment of pathobiological importance, such as tumor initiating cells, infiltrating cells, neo-vasculature, and GBM-infiltrating cells of monocytic origin like macrophages. Variants of this multivalent protein termed QUAD 2.0 and 3.0 contain an IgG1 scaffold, ephrinA5, which is a ligand for the EphA2, EphA3, and EphB2 receptors, and IL-13.E13K, a mutated version of interleukin 13 (IL-13) binding preferentially to IL-13RA2. In QUAD 3.0, a cysteine was added to the C-terminal end of QUAD 2.0 to allow effective conjugation to cytotoxic agents/labels. All QUAD variants bound effectively to the four receptors using ELISA with KD values of 100–200 pM for EphA2, EphA3, and IL-13RA2, and 700 pM-4 nM for EphB2, and downregulated the EphA2 and EphA3 receptors in GBM cells. QUAD 2.0 and 3.0 were conjugated to a modified form of Pseudomonas Exotoxin A and a modified doxorubicin. The conjugates were highly cytotoxic to established and primary GBM cells with IC50s &lt; 1.0 nM. Intracranial injections (1.3 mM, 5µL) of the conjugates were well tolerated in mice. Thus, targeting multiple receptors with a single multivalent protein is possible. One additional advantage in using these targeted cytotoxins is that they produce immunogenic cell death and can be combined with other approaches activating the immune system.
DDIS-28. A HIGH THROUGHPUT SCREENING PLATFORM TO IDENTIFY RADIOSENSITIZERS FOR DIPG
Authors: Matt Clutter, Megan Romero, Oren Becher
Journal: Neuro-Oncology (2019)

Abstract Diffuse intrinsic pontine glioma (DIPG) is an incurable brainstem tumor and the leading cause of death in children with brain cancer. Despite numerous clinical trials, no drugs have been found to prolong survival for DIPG patients, suggesting an urgent need to test therapeutics in preclinical models more predictive of clinical activity. To address this gap, we developed a genetically engineered mouse model incorporating the Histone H3.3 K27M mutation, p53 deletion, and PDGFR-α amplification, which co-occur in up to 40% of human DIPG. Here we report the results of a drug screen to identify radiosensitizers of DIPG cells isolated from our mouse model and cultured ex vivo as neurospheres. Although previous clinical trials combining radiotherapy with radiosensitizing agents failed to benefit DIPG patients, they incorporated general radiosensitizers. We hypothesize that searching for radiosynergy using 3-dimensional neurospheres derived from genetically defined primary cell DIPG models will enhance our ability to prioritize clinically relevant radiosensitizers. To identify candidates, we developed high throughput radiation and imaging protocols to quantify the number, size, and viability of neurospheres following treatment. We screened 1,280 FDA-approved drugs and 1,600 molecules with a history of clinical use. Two mechanistic classes of compounds were identified that sensitized DIPG neurospheres to radiotherapy, both targeting epigenetic factors. An HDAC1/3 inhibitor along with several different BET bromodomain inhibitors increased cell death 2–3 fold beyond the effect of radiation with minimal activity from the compounds alone. In addition to optimizing the dosing and timing of these compounds for animal studies, we are investigating whether radiosensitization occurs in H3.3 wildtype neurospheres. In the current molecular era of cancer, genetic features like the H3.3 K27M mutation could present an opportunity to develop therapeutics that preferentially radiosensitize diseased cells relative to normal cells. Such “precision radiosensitizers” would advance radiotherapy by enhancing tumor-specific toxicity while sparing bystander cells.
Extensive dissemination and intraclonal maturation of HIV Env vaccine-induced B cell responses
Authors: Ganesh E. Phad, Pradeepa Pushparaj, Karen Tran, Viktoriya Dubrovskaya, Monika Àdori, Paola Martinez-Murillo, Néstor Vázquez Bernat, Suruchi Singh, Gilman Dionne, Sijy O’Dell, Komal Bhullar, Sanjana Narang, Chiara Sorini, Eduardo J. Villablanca, Christopher Sundling, Benjamin Murrell, John R. Mascola, Lawrence Shapiro, Marie Pancera, Marcel Martin, Martin Corcoran, Richard T. Wyatt, Gunilla B. Karlsson Hedestam
Journal: The Journal of Experimental Medicine (2019)

Well-ordered HIV-1 envelope glycoprotein (Env) trimers are prioritized for clinical evaluation, and there is a need for an improved understanding about how elicited B cell responses evolve following immunization. To accomplish this, we prime-boosted rhesus macaques with clade C NFL trimers and identified 180 unique Ab lineages from ∼1,000 single-sorted Env-specific memory B cells. We traced all lineages in high-throughput heavy chain (HC) repertoire (Rep-seq) data generated from multiple immune compartments and time points and expressed several as monoclonal Abs (mAbs). Our results revealed broad dissemination and high levels of somatic hypermutation (SHM) of most lineages, including tier 2 virus neutralizing lineages, following boosting. SHM was highest in the Ab complementarity determining regions (CDRs) but also surprisingly high in the framework regions (FRs), especially FR3. Our results demonstrate the capacity of the immune system to affinity-mature large numbers of Env-specific B cell lineages simultaneously, supporting the use of regimens consisting of repeated boosts to improve each Ab, even those belonging to less expanded lineages.
Complete Endoscopic Healing Associated With Better Outcomes Than Partial Endoscopic Healing in Patients With Crohn’s Disease
Authors: Clara Yzet, Momar Diouf, Jean-Philippe Le Mouel, Franck Brazier, Justine Turpin, Julien Loreau, Jean Louis Dupas, Laurent Peyrin-Biroulet, Mathurin Fumery
Journal: Clinical Gastroenterology and Hepatology (2019)
Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study
Authors: Thomas E. Witzig, Lubomir Sokol, Francine M. Foss, Won-Seog Kim, Eric Jacobsen, Maria de Fatima De La Cruz, Dolores Caballero, Ranjana H Advani, Jose Maria Roncero, Raquel de Oña, Ana Marin Niebla, Antonia Rodriguez Izquierdo, Maria Jose Terol, Eva Domingo-Domenech, Miguel A. Piris, Marta Rodriguez, James Bolognese, Linda Kessler, Vishnu Mishra, Robert Curry, Michael Kurman, Catherine Scholz, Antonio Gualberto
Journal: Blood (2019)
Identification of New Polymorphisms in Genes of the Immune System Associated with Acute Graft Versus Host Disease after Identical HLA-Allogeneic Stem-Cell Transplantation
Authors: Paula Muñiz Sevilla, Carolina Martínez-Laperche, Mi Kwon, Rebeca Bailén, Nieves Dorado, Laura Solán, Diego Carbonell, Julia Suárez González, María Chicano Lavilla, Cristina Andres, Jose Maria Bellon, Juan Carlos Triviño, Javier Anguita, Jose L. Diez-Martin, Ismael Buño
Journal: Blood (2019)
INNV-10. SAFETY OF APIXABAN FOR VENOUS THROMBOEMBOLISM PREVENTION IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Authors: Alissa Thomas, Heather Wright, Hannah Walker, Prachi Prasad, Kelly Chan, Eswar Tipirneni, Andrew Goodwin, Chris Holmes
Journal: Neuro-Oncology (2019)

Abstract Venous thromboembolism (VTE) impacts an estimated one in every three patients with malignant glioma (MG), resulting in increased morbidity and mortality. Despite the high prevalence and serious consequences of VTE, there is no outpatient standard of care prevention strategy. There have been three prospective clinical trials of VTE prophylaxis in patients with newly diagnosed MG, all of which used an injectable low molecular weight heparin (LMWH) product. We performed an open-label safety study of apixaban, a direct oral anticoagulant (DOAC), for VTE prevention in patients with newly diagnosed MG. All patients had surgery or biopsy two to twenty-one days prior to enrollment in the study. Patients were treated with apixaban 2.5 mg twice daily for up to 6 months. Peak and trough apixaban concentrations were measured at the beginning and end of treatment. Thirteen patients consented to the study and ten enrolled (2 screen-fail, 1 withdrawal). The patients have completed a mean of 4.5 cycles of apixaban (range 2 to 6, with 2 patients still undergoing treatment). There were no bleeding events while receiving apixaban. There were no hematologic or non-hematologic treatment-related adverse events. There were no VTE events observed in patients receiving apixaban. Two patients who came off treatment early due to disease progression developed VTEs after stopping prophylactic apixaban. Quality of life analysis is ongoing. In this pilot study we found that prophylactic dosing of 2.5 mg twice daily of apixaban was safe in the post-operative period for patients with newly diagnosed MG. Our preliminary results suggest that this may be a safe and effective prevention strategy for VTE prophylaxis in this high risk group of patients.
Schistosomiasis in the West Indies
Authors: A. Compton
Journal: BMJ (1964)

Ruptured Ovarian Follicular Cyst SIR,-Simple follicular cysts of the ovary are very common and frequently rupture during examination.This may seem hazardous, but most textbooks are agreed that it does no harm.However, the following case illus- trates an exception to the general rule.A 36-year-cld gravida-5 gave this history.Her periods had been quite ncrrn3l.but she had had seven weeks' amenorrhoea followed by 18 days' continuous but slight bleeding.She was at first thought to have a threatened abortion and had been treated with rest and ethisterone, 25 mg.daily.After 12 days the loss increased and she developed labour-like abdominal pains.The abortion was now considered to be incomplete and ergometrine 0.5 mg.t.d.s.~was given for three days, but as slight bleeding persisted she was transferred to hospital.
Former Queen’s surgeon in Scotland was unfairly dismissed by NHS Grampian, says tribunal
Authors: Clare Dyer
Journal: BMJ (2019)

The Queen’s former surgeon in Scotland has won an employment tribunal claim for constructive unfair dismissal against NHS Grampian, his long term employer.1

Zygmunt Krukowski, a consultant surgeon at Aberdeen Royal Infirmary, resigned in April 2016, just before he was due to undergo a disciplinary process, handling of which was branded “incompetent” by the tribunal. He was surgeon to the Queen for 12 years, until May 2016.

He was awarded a personal chair in clinical surgery by the University of Aberdeen in 1999, and the tribunal agreed that he was “internationally renowned” and “a highly competent surgeon.”

Employment judge Alexander Meiklejohn, along with tribunal members Stuart Gray and Mary Williams Edgar, unanimously ruled that Krukowski was constructively dismissed by NHS Grampian when he resigned in response to material …
Screening of House Dust from Chinese Homes for Chemicals with Liver X Receptors Binding Activities and Characterization of Atherosclerotic Activity Using an <i>in Vitro</i> Macrophage Cell Line and ApoE−/− Mice
Authors: Wenxin Hu, Yingting Jia, Qiyue Kang, Hui Peng, Haojia Ma, Shiyi Zhang, Youhei Hiromori, Tomoki Kimura, Tsuyoshi Nakanishi, Lemin Zheng, Yifu Qiu, Zhaobin Zhang, Yi Wan, Jianying Hu
Journal: Environmental Health Perspectives (2019)

BACKGROUND: Atherosclerotic cardiovascular disease has become the leading cause of death worldwide, and environmental pollutants are increasingly recognized as risk factors for atherosclerosis.Liver X receptors (LXRs) play a central role in atherosclerosis; however, LXR activity of organic pollutants and associated potential risk of atherosclerosis have not yet been characterized.OBJECTIVES: This study aimed to explore whether LXR-antagonistic chemicals are present in indoor house dust and, if so, to characterize this activity in relation to changes in macrophages in vitro and cardiovascular disease indicators in vivo in an atherosclerosis ApoE -= -mouse model.METHODS: We used a His-LXRa-pull-down assay and a nontarget high-resolution mass spectrometry method to screen house dust collected from Chinese homes for LXRa-and LXRb-antagonist activity.A chemical identified in this manner was assessed for its ability to induce cholesterol efflux and foam cell formation in RAW264.7 macrophages, to down-regulate the expression of two LXR-dependent genes, ABCA1 and ABCG1, and finally to induce atherosclerotic lesions in vivo using an ApoE -=-mouse model.RESULTS: We identified the flame retardants triphenyl phosphate (TPHP) and 2-ethylhexyl diphenyl phosphate (EHDPP) in house dust samples and demonstrated their ability to antagonize LXRs.The potency of TPHP was similar to that of the LXR-antagonist SR9238.TPHP could also inhibit cholesterol efflux and promote foam cell formation in RAW264.7 macrophages and mouse peritoneal macrophages and significantly promoted atherosclerotic lesion formation in the ApoE -=-mouse model.CONCLUSIONS: We found LXR-antagonist chemicals in environmental samples of indoor dust from Chinese homes.One of the chemicals, TPHP, was able to promote the development of atherosclerotic lesions in the ApoE -= -mouse model.These results highlight the need to assess the LXRantagonist activities of pollutants in future environmental management programs.
SUDS3 regulates BRMS1-mediated phenotypes by affecting SIN3-HDAC complex composition
Authors: Alexandra Silveira, Douglas Hurst, Yi Xie, Danny Welch
Journal: Cancer Research (2008)

2484  The involvement of Breast Cancer Metastasis Suppressor 1 (BRMS1) in SIN3-HDAC chromatin remodeling complexes has been implicated as a mechanism by which BRMS1 can suppress metastasis. This involvement is thought to be mediated by the direct interaction of BRMS1 with the SIN3-HDAC complex components SUDS3 and ARID4A. In yeast, SUDS3 acts as a scaffolding protein that stabilizes SIN3-HDAC complexes. We hypothesized that direct interaction of SUDS3 and BRMS1 regulates the composition of these complexes and, thus, regulates the transcription of genes required for metastasis. Mutational analysis showed that deletion of the first coiled-coil domain results in a BRMS1 mutant, BRMS1ΔCC1, that does not interact with SUDS3 in yeast two hybrid genetic screens. While BRMS1ΔCC1 still directly interacts with ARID4A in yeast, it was unable to co-immunoprecipitate ARID4A in MDA-MB-435 cells. These data suggest that the interaction of SUDS3 with BRMS1 is necessary for the formation of a BRMS1-protein complex containing ARID4A and, moreover, suggests that SUDS3 influences the composition of BRMS1-SIN3-HDAC protein complexes. Unlike wild-type BRMS1, BRMS1ΔCC1 did not decrease levels of PtdIns(4,5)P2. However, like wild-type, BRMS1ΔCC1 completely down-regulated expression of Epidermal Growth Factor Receptor in MDA-MB-435 cells. Through more refined mutational analysis, the site of BRMS1:SUDS3 interaction is being mapped to confirm that these and other results are a direct effect of disrupting this interaction. Taken together these data indicate that the interaction of SUDS3 and BRMS1, at least partially, dictates the composition of BRMS1-SIN3-HDAC complexes to alter specific (i.e., not all) BRMS1-mediated phenotypes. These insights into the formation of BRMS1-SIN3-HDAC complexes can lead to a better understanding of how BRMS1 regulates transcriptional events to suppress metastasis.  Support: CA87728, F32CA113037, Natl. Fndn Cancer Res
Infectious Complications Associated with CAR T-Cell Therapy
Authors: Lekha Mikkilineni, Shilpa Shahani, Bonnie Yates, Seth M. Steinberg, Tara Palmore, Veronique Nussenblatt, Daniel W. Lee, Rosandra N. Kaplan, Crystal L. Mackall, Terry J. Fry, Juan Gea-Banacloche, Theresa Jerussi, James N. Kochenderfer, Nirali N. Shah
Journal: Blood (2019)
Mannose is an insulin-regulated metabolite reflecting whole-body insulin sensitivity in man
Authors: E. Ferrannini, M. Bokarewa, P. Brembeck, R. Baboota, S. Hedjazifar, K. Andersson, S. Baldi, B. Campi, E. Muscelli, A. Saba, I. Sterner, C. Wasen, U. Smith
Journal: Metabolism (2019)
IMMU-01. MYELOID-DERIVED SUPPRESSOR CELL HETEROGENEITY DRIVES GLIOBLASTOMA PROGRESSION IN A SEX-DEPENDENT MANNER
Authors: Defne Bayik, Daniel Silver, Chihyun Park, Dionysios Watson, Mia Sorensen, Gustavo Roversi, Adam Lauko, Tyler Alban, Alice Lo, Peter Sims, Jill Barnholtz-Sloan, Bjarne Kristensen, Tae Hyun Hwang, Ahmad Khalil, Antonio Iavarone, Feixiong Cheng, Justin Lathia
Journal: Neuro-Oncology (2019)

Abstract An immunosuppressive tumor microenvironment is a major factor facilitating glioblastoma (GBM) progression and therapeutic resistance. Immunotherapies have had variable success in improving the outcome of GBM patients, suggesting that there is a need to gain insight into the mechanisms of immunosuppression. Our group previously demonstrated that myeloid-derived suppressor cells (MDSCs) expand in GBM patients and infiltrate tumors, where they suppress the activity of cytotoxic cells. However, the mechanisms by which individual MDSC subsets promote tumorigenesis remain understudied. Using the syngeneic mouse glioma models GL261, CT-2A and SB28, we show that monocytic MDSCs (mMDSCs) are prevalent in tumors and that their frequency is significantly higher in males, who constitute 60% of GBM patients and have a worse prognosis than females. mMDSC abundance was further associated with poor survival, and male mice reached morbidity endpoint earlier. Consistent with preclinical observations, male GBM patient specimens had significantly more IBA+CD204+ immunosuppressive myeloid cells compared to female GBM tissue. In contrast, female tumor-bearing mice had a two-fold increase in circulating granulocytic MDSC (gMDSC) frequency, while this population remained unchanged in males. Female-to-male bone marrow chimeras demonstrated that intrinsic discrepancies in immune cell characteristics drive the sex differences in survival. Consistent with the differential MDSC accumulation pattern, targeting gMDSCs with anti-Ly6G neutralizing antibodies extended the lifespan of female mice without providing a survival advantage to males. However, mMDSCs were protected from the anti-Ly6C depletion strategy due to their systemic and local proliferation, as indicated by ex vivo Ki-67 staining and subsequently confirmed by gene expression analysis. Drug-prediction algorithms using the differential RNA sequencing profiles demonstrated that mMDSCs can be targeted by chemotherapeutics, while immunomodulatory drugs are effective against gMDSCs. Collectively, these findings indicate that MDSC subset variation might represent a therapeutic opportunity for improved therapeutic efficacy of immunotherapies while accounting for sex as a biological variable.
The Real Life Accessibility to CAR T-Cell Therapy: Current Experience in the Only Active Center in Italy
Authors: Anna Guidetti, Giulia Perrone, Paola Coluccia, Luca Fumagalli, Anna Dodero, Lucia Farina, Flavio Arienti, Filippo Bagnoli, Luca Pappalettera, Debora Degli Innocenti, Cristiana Carniti, Daniela Codazzi, Paolo Corradini
Journal: Blood (2019)
Isolated Immunoglobulin G4–Related Disease of Nasal Septum and Maxilla
Authors: Omar Dario Rodriguez Fonseca, Juan Pablo Suarez, Maria Luz Dominguez, Belen Fernandez Llana, Carmen Vigil, Noelia Martin, Francisco Manuel Gonzalez
Journal: Clinical Nuclear Medicine (2019)

Abstract Immunoglobulin G4–related disease (IgG4-RD) is a systemic inflammatory condition that can manifest in atypical locations. We present the case of a middle-aged woman presenting with isolated IgG4-RD of left maxilla and nasal septum, confirmed with 18 F-FDG PET/CT. She achieved complete metabolic response with multiple pharmacologic treatment, but 1 year later, she experienced local relapse, and FDG PET/CT found new additional lesions in humeral vasculature and lungs. This case illustrates the usefulness of FDG PET/CT for initial evaluation and monitoring of IgG4-RD with unusual nasomaxillary involvement.
Randomized Study of Systematic Biopsy Versus Magnetic Resonance Imaging and Targeted and Systematic Biopsy in Men on Active Surveillance (ASIST): 2-year Postbiopsy Follow-up
Authors: Laurence Klotz, Greg Pond, Andrew Loblaw, Linda Sugar, Madeline Moussa, David Berman, Theo Van der Kwast, Danny Vesprini, Laurent Milot, Marlene Kebabdjian, Neil Fleshner, Sangheet Ghai, Joseph Chin, Masoom Haider
Journal: European Urology (2019)
Novel Evidence That Extracellular Adenosine Triphosphate (ATP), As a Purinergic Signaling Mediator, Activates Mobilization By Engaging a P2X4 Ligand-Gated Cation Channel Receptor Expressed on the Surface of Hematopoietic and Innate Immunity Cells
Authors: Kamila Bujko, Mateusz Adamiak, Arjun Thapa, Magdalena Kucia, Janina Ratajczak, Mariusz Z Ratajczak
Journal: Blood (2019)